About ZGBiotech
ZGBiotech is a company based in Shanghai (China) founded in 2017.. ZGBiotech has raised $235.75 million across 4 funding rounds from investors including Qiming Venture Partners, Goldman Sachs Asset Management and Sofina. ZGBiotech operates in a competitive market with competitors including OBiO Technology, Daewoong Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Chime Biologics and Tot Biopharm, among others.
- Headquarter Shanghai, China
-
Sectors
HealthcareIndustrial Goods & Manufacturing
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$235.75 M (USD)
in 4 rounds
-
Latest Funding Round
$14.75 M (USD), Series C
Aug 18, 2022
-
Investors
Qiming Venture Partners
& 15 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ZGBiotech
ZGBiotech has successfully raised a total of $235.75M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $14.75 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $14.7M
-
First Round
First Round
(30 Mar 2020)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2022 | Amount | Series C - ZGBiotech | Valuation | Qiming Venture Partners | |
| Jan, 2022 | Amount | Series C - ZGBiotech | Valuation | Sofina , Goldman Sachs Investment Partners | |
| Mar, 2021 | Amount | Series B - ZGBiotech | Valuation | IDG Capital , Qiming Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ZGBiotech
ZGBiotech has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiming Venture Partners, Goldman Sachs Asset Management and Sofina. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are provided by Sofina to emerging companies.
|
Founded Year | Domain | Location | |
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Venture capital investments are directed toward multiple sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ZGBiotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ZGBiotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Zgbiotech Comparisons
Competitors of ZGBiotech
ZGBiotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OBiO Technology, Daewoong Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Chime Biologics and Tot Biopharm, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
OBiO Technology is engaged in cell and gene therapy solutions.
|
|
| domain | founded_year | HQ Location |
Therapies for gastrointestinal disorders and related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Heparin Sodium API and derivatives are manufactured for global markets.
|
|
| domain | founded_year | HQ Location |
Biopharma contract development and manufacturing services are provided.
|
|
| domain | founded_year | HQ Location |
-
|
|
| domain | founded_year | HQ Location |
Small molecules and immunologicals are developed and manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Zgbiotech
Frequently Asked Questions about ZGBiotech
When was ZGBiotech founded?
ZGBiotech was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Where is ZGBiotech located?
ZGBiotech is headquartered in Shanghai, China.
Is ZGBiotech a funded company?
ZGBiotech is a funded company, having raised a total of $235.75M across 4 funding rounds to date. The company's 1st funding round was a Series B of $70M, raised on Mar 30, 2020.
What does ZGBiotech do?
ZGBiotech was founded in 2017 and is based in Shanghai, China. Operations are centered on the biotechnology sector as a contract development and manufacturing organization. Analytical development, formulation processes, and quality testing services are offered to support drug development projects. These capabilities are utilized by pharmaceutical partners for regulatory compliance and product advancement in the region.
Who are the top competitors of ZGBiotech?
ZGBiotech's top competitors include OBiO Technology, Daewoong Pharmaceutical and Chime Biologics.
Who are ZGBiotech's investors?
ZGBiotech has 16 investors. Key investors include Qiming Venture Partners, Goldman Sachs Asset Management, Sofina, Novo Holdings, and IDG Capital.